PLK4 and neuroblastoma: We then show that 17q gain including the TRIM37 locus is a near universal feature of high-risk neuroblastoma and that RP-1664 shows robust single agent efficacy across a panel of human neuroblastoma cell line derived xenograft (CDX) and patient-derived xenograft (PDX) models, as well as a genetically engineered mouse model (GEMM) of this disease, supporting clinical development of PLK4 inhibition strategies for high-risk neuroblastoma.